New pill aims to fight silent liver scourge
NCT ID NCT03468556
Summary
This study is testing if a new oral drug called SNP-610 can help control non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease that can lead to scarring and liver failure. About 80 adults in Taiwan with confirmed NASH will take either the drug or a placebo pill daily for 3 months. Researchers will check if the drug safely reduces liver enzyme levels and the amount of fat in the liver.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASH - NONALCOHOLIC STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.